Thrombelastography (TEG®)

González, Eduardo; Moore, Ernest E.; Moore, Hunter B.

doi:10.1007/978-3-319-28308-1_17

Cited by 1 publication

(1 citation statement)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lower MA value with a specific activator indicates greater platelet inhibition by the drug. Together, these TEG‐PM parameters offer a comprehensive assessment of a patient's platelet function and the effectiveness of antiplatelet therapy 6–8 . Given that women have an increased risk of both amputation and poor wound healing in spite of having lower risk factors than their male counterparts, we hypothesized that platelets in women may respond differently to the standard of care antiplatelet medication aspirin compared to men.…”

Section: Introductionmentioning

confidence: 99%

The impact of sex on platelet responses to aspirin in patients with peripheral artery disease

Suarez Ferreira,

Hall,

Morrow

et al. 2024

American J Hematol

View full text Add to dashboard Cite

Women with peripheral artery disease (PAD) have poorer limb salvage outcomes in spite of having lower risk factors for vascular disease than their male counterparts. Mono antiplatelet therapy with aspirin is the cornerstone of medical treatment for PAD to reduce the risk of arterial thrombosis, but platelets in women may have a variable response to this standard of care compared to men. Viscoelastic assays, such as thromboelastography with platelet mapping (TEG‐PM), have been utilized to identify prothrombotic states and may provide insight into a patient's real‐time coagulation profile and their response to specific antiplatelet medications. The aim of this prospective, observational study was to delineate the sex differences in platelet function using TEG‐PM in patients with PAD on aspirin post‐revascularization for PAD. All patients with PAD undergoing revascularization on aspirin monotherapy were prospectively enrolled between December 2020 and September 2023. The cohort was divided by sex, demographics, medications, procedure type, and outcomes were documented. Serial perioperative TEG‐PM assays (1, 3, and 6 months) were performed up to 6 months postoperatively and platelet function was evaluated in both groups. Statistical analysis between women and men was performed to identify sex‐specific differences in platelet function. Over the study period, a total of 303 patients were enrolled. Of this cohort, 149 patients met the study criteria and 266 samples were analyzed; 52 (34.89%) were women and 97 (65.11%) were men. In the platelet mapping assay, women showed significantly greater MAActF and MAAA, than men (16.66 vs. 14.94, p < .03 and 37.26 vs. 32.38, p < .01, respectively) indicating stronger thrombotic propensity. Additionally, platelet inhibition was significantly lower in women compared to men (52.95% vs. 61.65%, p < .05). In clinical outcomes reported as thrombotic events, women showed significantly higher occlusion in the area of intervention than men (4 vs. 1, p < .05). There is a growing awareness of the variations in the natural course, underlying mechanisms, and resulting outcomes of cardiovascular conditions, including PAD, in relation to sex. In this study, women did not achieve the same levels of platelet inhibition and displayed a procoagulant tendency in comparison to men when administered aspirin. Overall, aspirin monotherapy may be potentially sufficient for men, but women may require increased doses and/or additional antiplatelet medications to achieve an equivalent therapeutic effect.

show abstract

Section: Introductionmentioning

confidence: 99%